{
  "id": "thymoma",
  "title": "Thymoma",
  "lang": "en",
  "source_lang": "en",
  "summary": "Thymoma is a rare thymic epithelial tumor with malignant potential and distinctive associations with autoimmune disease.",
  "category": "health",
  "subcategory": "diseases",
  "type": "concept",
  "aliases": [],
  "generated_at": "2026-10-22",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/thymoma/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/thymoma/",
      "json": "https://aiwiki.page/zh/thymoma.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Thymoma is a tumor arising from the epithelial cells of the thymus, usually in the anterior mediastinum, the compartment behind the breastbone. It is distinct from thymic carcinoma and commonly contains non-neoplastic developing T cells among its tumor cells. Although some thymomas grow slowly and remain localized, all have malignant potential, including the capacity to invade surrounding structures or spread beyond their original site. (cancer.gov)\n\nThymoma is notable for its association with disorders of the immune system, particularly myasthenia gravis, pure red cell aplasia, and thymoma-associated immunodeficiency, also called Good syndrome. Its evaluation combines imaging, pathological classification, and assessment of disease extent. Treatment centers on surgical removal when feasible, with radiation therapy and systemic treatment used in selected disease settings; prognosis depends substantially on stage and completeness of resection. (cancer.gov)"
    },
    {
      "heading": "Anatomical Origin and Disease Boundaries",
      "text": "Thymoma arises from the epithelial cells of the thymus, an organ situated predominantly in the anterior, or prevascular, mediastinum—the compartment behind the breastbone and in front of the heart and major vessels. The thymus contains both epithelial tissue and developing lymphocytes; its normal function includes the maturation of T cells. Its location explains why thymoma usually presents anatomically as an anterior mediastinal mass rather than as a lung tumor, although both occupy the chest. (cancer.gov)\n\nThe defining neoplastic population in thymoma is epithelial. The accompanying lymphocytes, often immature T cells called thymocytes, are non-neoplastic and occur in widely varying proportions. Consequently, a lymphocyte-rich thymoma can contain many more lymphocytes than readily recognizable tumor cells without being a lymphoma. Conversely, a thymoma with few lymphocytes remains within the same disease family. The distinction concerns which cellular population is neoplastic, not simply which population dominates a tissue section. Thymomas generally preserve some microscopic resemblance to normal thymic tissue, despite substantial variation in their epithelial and lymphoid components. (cancer.gov)\n\nThymoma is one category within the broader group of thymic epithelial tumors, not a collective name for every tumor arising in the thymus. The International Collaboration on Cancer Reporting’s May 2022 reporting guide, aligned with the 2021 World Health Organization classification of thoracic tumors, covers thymoma, thymic carcinoma, and thymic neuroendocrine neoplasms as distinct diagnostic groups. Its scope excludes germ cell tumors, hematolymphoid neoplasms, and soft-tissue tumors, even when these arise within the thymus or occupy the same mediastinal compartment. Anatomical location alone therefore does not establish a diagnosis of thymoma. (iccr-cancer.org)\n\nThymic carcinoma differs from thymoma by overtly malignant epithelial cytology and loss of characteristic thymus-like microscopic features; it is not merely a thymoma that has invaded neighboring tissue. Thymic neuroendocrine neoplasms constitute another separate group, encompassing typical and atypical carcinoid tumors as well as small-cell and large-cell neuroendocrine carcinomas. These distinctions separate tumor identity from anatomical extent: an invasive thymoma remains a thymoma unless the tissue supports a different diagnosis. (cancer.gov)\n\nAn apparently complete capsule or bland-looking epithelial cells does not make a thymoma biologically benign. All thymic epithelial tumors have malignant potential, and microscopic appearance alone cannot reliably distinguish indolent from aggressive thymoma. Encapsulation describes the tumor’s boundary at examination, whereas invasion describes growth into surrounding structures. Accordingly, the ICCR guide records histological identity separately from involvement of mediastinal pleura, pericardium, lung, and major vessels. A bland epithelial appearance and demonstrable tissue invasion can coexist in the same tumor. (cancer.gov)"
    },
    {
      "heading": "Epidemiology and Established Risk Patterns",
      "text": "Thymoma is rare: the US National Cancer Institute’s PDQ summary cites an incidence of approximately 0.13 cases per 100,000 person-years, equivalent to about 1.3 newly diagnosed cases per million people annually. This estimate derives from the US Surveillance, Epidemiology, and End Results (SEER) cancer registries, not from worldwide surveillance. Eric A. Engels’s 2010 analysis, cited by the PDQ summary, examined US registry data, including SEER9 observations from 1973–2006. The figure describes new diagnoses relative to accumulated population observation time; it is neither the proportion of people living with thymoma nor an individual’s lifetime probability of developing it. Its interpretation therefore requires the population, observation period, and registry definitions to remain explicit. (cancer.gov)\n\nThe age distribution is strongly adult-predominant. Thymoma is exceptionally uncommon in children and young adults, becomes more frequent in middle age, and remains principally a disease of middle-aged and older adults. Engels’s 2010 SEER analysis reported an age-specific incidence peak in the seventh decade of life. This is a population incidence pattern, rather than a minimum diagnostic age: childhood cases occur, but they represent an exceptional presentation, not a substantial component of the disease burden. The increasing incidence with age establishes a demographic association; it does not, by itself, identify the biological events responsible for tumor development. (pubmed.ncbi.nlm.nih.gov)\n\nUS registry studies also show differences between population groups. Engels identified particularly high thymoma incidence among Asian and Pacific Islander populations. The American Cancer Society likewise describes higher thymus-cancer occurrence among Asian Americans, Native Hawaiians, and Pacific Islanders, and higher occurrence among Black than White people. These categories describe observed demographic distributions, not demonstrated causal exposures or specific inherited susceptibilities. In particular, a higher registry rate in a population group does not establish that ethnicity itself causes thymoma or that an individual within that group has a high absolute risk; the tumor remains rare. (pubmed.ncbi.nlm.nih.gov)\n\nNo specific inherited, environmental, or lifestyle-related risk factor has been strongly established for thymoma. Consequently, there are no well-established modifiable exposures that explain its occurrence. A possible relationship with radiation exposure to the upper chest has been suggested in some studies but remains unconfirmed. The distinction between an unknown cause and a proven absence of environmental influence is important: limited evidence does not demonstrate that such influences are impossible. Thymoma’s rarity also restricts the size of epidemiological studies, making suspected associations difficult to evaluate reliably. (cancer.org)\n\nAssociated autoimmune diseases must be distinguished from antecedent causes. Myasthenia gravis is strongly associated with thymoma, while pure red cell aplasia and hypogammaglobulinemia are other recognized accompanying disorders. Their coexistence does not establish that they initiated the tumor. The NCI describes thymoma-associated autoimmunity in relation to abnormal selection of T cells, providing a biological basis for immune disease accompanying a thymic tumor rather than evidence that pre-existing autoimmunity is a demonstrated carcinogenic exposure. These immune associations therefore belong to the clinical and biological disease pattern, not to a list of proven preventable causes. (cancer.org)"
    },
    {
      "heading": "Histopathology and WHO Classification",
      "text": "Thymomas commonly show lobules separated by fibrous septa, with epithelial cells admixed with variable numbers of non-neoplastic T lymphocytes. The epithelial component may consist of slender spindle cells, oval cells, or larger polygonal cells; in lymphocyte-rich tumors, it can be difficult to recognize on routine hematoxylin-and-eosin sections. Perivascular spaces—clear spaces surrounding blood vessels—are another characteristic architectural feature. Immunohistochemistry supports interpretation rather than replacing morphology: cytokeratins and p63 highlight epithelial cells, whereas terminal deoxynucleotidyl transferase (TdT) identifies immature lymphocytes. This distinction establishes which cells constitute the epithelial tumor and which represent accompanying thymocytes; abundant lymphocytes do not themselves make the lesion a lymphoma. (thymic.org)\n\nThe 2021 fifth edition of the World Health Organization classification recognizes the principal types A, AB, B1, B2, and B3. Type A contains bland spindle or oval epithelial cells with few or no immature T cells. Type AB combines an A-like epithelial population with lymphocyte-rich areas, which may be sharply separated or intermingled. Type B1 resembles the normal functional thymus: immature T cells dominate, epithelial cells are inconspicuous and dispersed, and paler medullary islands are characteristic. Type B2 also contains abundant immature T cells, but its larger polygonal epithelial cells are more numerous and readily visible, individually and in clusters. Type B3 is epithelial-predominant, with sheets of polygonal cells, relatively sparse lymphocytes, and usually mild to moderate nuclear atypia. These designations describe microscopic patterns, not anatomical stages; neither subtype nor cytological blandness establishes whether a tumor has invaded adjacent structures. (thymic.org)\n\nHistological heterogeneity requires explicit documentation. The International Collaboration on Cancer Reporting (ICCR) 2022 dataset specifies that, when several thymoma patterns coexist, each should be listed in 10% increments, beginning with the predominant component—for example, “type B2, 70%; type B3, 30%.” Type AB is an exception: its characteristic mixture is a single entity and is recorded as “type AB, 100%,” rather than divided into A and B percentages. A genuine thymic carcinoma component changes the designation to “combined thymic carcinoma and thymoma,” with the carcinoma component specified first regardless of its proportion. (iccr-cancer.org)\n\nUncommon entities are recorded by their specific names rather than forced into the A–B3 sequence. Micronodular thymoma with lymphoid stroma consists of small epithelial nodules separated by prominent lymphoid tissue, often containing follicles with germinal centers. Metaplastic thymoma has a biphasic appearance, combining epithelial islands with bland spindle-cell areas. The classification also recognizes an atypical type A variant, in which features such as increased mitotic activity, nuclear crowding, and comedo-type necrosis warrant documentation. These distinctions concern tumor architecture and cellular composition, not separate staging categories. (pmc.ncbi.nlm.nih.gov)\n\nThe resection report records tumor dimensions, directly involved structures, and resection margins separately from histological subtype. Specifying involvement of structures such as pericardium or lung supplies anatomical information that the WHO label cannot convey. Margin assessment identifies whether tumor reaches a surgical cut surface and, when involved, its location. After preoperative treatment, reporting can include the estimated percentage of viable tumor across the tumor bed, together with fibrosis, necrosis, and other treatment-associated changes. The ICCR 2022 guide treats treatment response as a non-core reporting element and notes the absence of a well-established thymic-tumor regression scoring system; these changes should not automatically be assigned the prognostic meaning established in other cancers. (iccr-cancer.org)"
    },
    {
      "heading": "Molecular Biology and Immune Dysregulation",
      "text": "In 2018, Milan Radovich and colleagues in The Cancer Genome Atlas (TCGA) reported an integrated analysis of 117 thymic epithelial tumors, including thymomas and thymic carcinomas. They combined DNA sequencing with measurements of chromosome copy number, DNA methylation, RNA expression, and protein abundance. Four molecular groups broadly corresponded to B-type thymomas, thymic carcinoma, predominantly AB thymomas, and a mixture of A and AB thymomas. These groupings complemented morphological classification rather than replacing it: molecular profiles reflected both epithelial tumor biology and differences in accompanying lymphocyte content. (pmc.ncbi.nlm.nih.gov)\n\nThymomas have an unusually low tumor mutational burden—the number of acquired DNA mutations relative to the amount of genome examined—compared with other adult cancers. Nevertheless, recurrent alterations occur in specific genes, particularly GTF2I, with additional mutations involving HRAS, NRAS, and TP53. Low overall mutation counts therefore do not imply an absence of molecular drivers. The TCGA findings identified candidate biological targets, but neither the molecular groups nor the recurrent GTF2I alteration established a validated biomarker for selecting a particular drug; identifying a recurrent mutation and demonstrating that it predicts treatment benefit are separate evidentiary steps. (cancer.gov)\n\nThe association between GTF2I and particular histological subtypes preceded TCGA. In 2014, Iacopo Petrini and colleagues reported the recurrent missense alteration in 82% of type A and 74% of type AB thymomas in a series of 274 thymic epithelial tumors. The mutation substitutes histidine for leucine in the encoded transcription factor and is commonly designated p.L424H. Mutant forms stimulated cell proliferation in laboratory experiments, supporting a role in tumor development. Its association with favorable outcomes in that study also reflected its concentration in less aggressive histological subtypes, rather than establishing a treatment-predictive effect. (pmc.ncbi.nlm.nih.gov)\n\nImmune dysfunction concerns the tumor’s capacity to support T-cell development without reproducing the normal thymic mechanisms of central immune tolerance. Normally, developing T cells undergo selection that removes strongly self-reactive populations, while regulatory T cells restrain potentially harmful immune responses. The autoimmune regulator protein, AIRE, contributes by promoting thymic expression of tissue-restricted self-antigens. In a 2007 study comparing 36 thymomas with 21 non-neoplastic thymic specimens, AIRE RNA expression was 8.5-fold higher in non-neoplastic tissue. Thymomas also contained fewer FOXP3-positive regulatory T cells. These findings support a model in which disorganized epithelial differentiation and deficient tolerance mechanisms permit self-reactive lymphocytes to develop or escape normal control. However, similarly low AIRE expression occurred in tumors from patients with and without myasthenia gravis, showing that this abnormality alone does not explain who develops autoimmunity. (pmc.ncbi.nlm.nih.gov)\n\nTCGA provided a complementary molecular association: myasthenia gravis–associated tumors showed increased aneuploidy, meaning abnormal chromosome number, and overexpression of muscle autoantigens. These observations link altered tumor genomes and gene expression to potential targets of autoimmune responses, but do not establish that chromosome imbalance directly causes the disease. More recent single-cell and spatial analyses have identified developing T cells at multiple maturation stages within thymomas, reduced regulatory T-cell abundance, and defective epithelial expression of molecules involved in selection. Together, these findings support continued but abnormal T-cell development within the tumor; the sequence connecting these defects to a particular autoimmune disorder remains incompletely resolved. (pubmed.ncbi.nlm.nih.gov)"
    },
    {
      "heading": "Clinical Presentation and Associated Syndromes",
      "text": "Thymoma may be clinically silent and discovered incidentally on a chest radiograph or computed tomography scan obtained for another reason. Symptomatic tumors can produce persistent cough, chest discomfort, or breathlessness through pressure on nearby mediastinal structures. Esophageal compression may cause difficulty swallowing. Compression of the superior vena cava impedes venous return from the upper body, producing swelling of the face, neck, and arms, distended superficial veins, headache, and sometimes respiratory distress. Hoarseness and phrenic nerve palsy are other recognized local manifestations. These mass-related effects are distinct from associated immune syndromes, which do not require direct compression or invasion of the affected organ. (cancer.org)\n\nMyasthenia gravis is the most frequent autoimmune disorder associated with thymoma. The direction of the association matters: the National Cancer Institute summarizes reported series in which approximately 30–65% of patients with thymoma had myasthenia gravis, whereas commonly cited estimates indicate that only about 10–15% of patients with myasthenia gravis have a thymoma. Thus, the frequency of myasthenia among thymoma patients must not be interpreted as the probability of thymoma in someone with myasthenia. Thymoma-associated disease commonly involves autoantibodies against the acetylcholine receptor, disrupting transmission of signals from nerves to skeletal muscles. (cancer.gov)\n\nThe characteristic myasthenic manifestation is fatigable weakness rather than generalized tiredness alone. Ocular involvement produces drooping eyelids and double vision; bulbar involvement affects speech, chewing, and swallowing. Limb weakness may become apparent during activities such as climbing stairs, while weakness of the diaphragm and other respiratory muscles can cause severe ventilatory impairment. Myasthenic symptoms may bring an otherwise unsuspected thymoma to clinical attention, and patients with associated autoimmune syndromes are often diagnosed at an earlier tumor stage. Nevertheless, removal of the tumor does not invariably eliminate the neuromuscular disorder. (cancer.org)\n\nPure red cell aplasia selectively impairs red blood cell production, causing anemia with profound reticulocytopenia and marked depletion of erythroid precursors in the bone marrow; other blood-cell lineages are generally preserved. Its manifestations include pallor, weakness, dizziness, exertional breathlessness, and fatigue, rather than the activity-dependent weakness characteristic of myasthenia. The National Cancer Institute gives an approximate frequency of 4% among thymoma patients. The hematological disorder can follow a course separate from the tumor: in a Japanese nationwide study published in 2008 by Makoto Hirokawa and colleagues, 16 patients developed pure red cell aplasia after thymoma removal, at a median interval of 80 months. (cancer.org)\n\nGood syndrome is thymoma-associated immunodeficiency characterized by hypogammaglobulinemia—reduced concentrations of circulating infection-fighting antibodies. B-cell depletion and abnormalities of cellular immunity can accompany the antibody deficiency, increasing susceptibility to recurrent or opportunistic infections. Its clinical presentation therefore contrasts with the predominantly anemic manifestations of pure red cell aplasia, although associated syndromes can coexist. In a 2021 single-center study by Yueting Li and colleagues at Peking Union Medical College Hospital, 23 of 24 patients with Good syndrome had documented infections, most frequently involving the lungs. Immune-associated illness may remain clinically important after tumor-directed treatment; thymectomy does not consistently resolve these disorders. (cancer.gov)"
    },
    {
      "heading": "Diagnostic Evaluation and Differential Diagnosis",
      "text": "Intravenous contrast-enhanced chest computed tomography (CT) is the principal imaging examination for a suspected thymoma. It establishes the mass’s location, dimensions, contour, and internal composition, while assessing its relationship to the pericardium, lungs, and major vessels and examining the pleural surfaces for separate deposits. These anatomical findings help determine whether complete surgical removal appears feasible, although imaging does not establish the histological diagnosis. Magnetic resonance imaging (MRI) provides additional characterization when CT is indeterminate, particularly for cystic lesions or suspected thymic hyperplasia, and can further assess possible mediastinal invasion. It is also an alternative when iodinated contrast material cannot be administered. (gethi.org)\n\nChemical-shift MRI helps distinguish hyperplasia from a solid thymic neoplasm by detecting microscopic fat: signal reduction on opposed-phase images supports fat-containing, non-neoplastic thymic tissue. A preserved, relatively symmetrical thymic configuration and a history of recovery after physiological stress or chemotherapy also support rebound hyperplasia. Thymic cysts enter the differential when a lesion has fluid characteristics; MRI is particularly useful when CT cannot confidently establish its cystic nature. Fluorodeoxyglucose positron emission tomography (FDG-PET) is not a definitive discriminator. The 2021 SEOM–GECP–GETTHI guideline reported sensitivity of 83% and specificity of 58% for thymic masses, illustrating its limited specificity. PET is therefore not a routine substitute for anatomical imaging or tissue examination, although it may clarify suspected advanced or recurrent disease. (gethi.org)\n\nOther anterior mediastinal masses require integration of clinical, laboratory, and pathological findings. Lymphoma becomes more likely with rapidly developing systemic symptoms, extensive lymphadenopathy, or elevated lactate dehydrogenase, but these findings are not diagnostic. A teratoma may contain a heterogeneous mixture of fat and cystic components. Elevated alpha-fetoprotein supports a nonseminomatous germ-cell tumor, whereas beta-human chorionic gonadotropin can be elevated in seminoma and other germ-cell tumors. Thyroid-origin masses and thymic carcinoma are additional alternatives. Neither an associated autoimmune disorder nor an apparently characteristic scan eliminates the need for histological confirmation of the final diagnosis. (thymicuk.org)\n\nThe timing of tissue sampling depends on the likely diagnosis and resectability. When imaging strongly suggests a thymic epithelial tumor and complete initial resection appears achievable, surgery may provide both treatment and the specimen for definitive pathological examination, without a preceding needle biopsy. Conversely, a mass requiring induction or nonsurgical treatment generally undergoes pretreatment biopsy; suspected lymphoma likewise requires tissue diagnosis before disease-specific therapy. Percutaneous core-needle biopsy or an incisional surgical biopsy can supply tissue for morphological and immunohistochemical assessment. Fine-needle aspiration alone is generally discouraged because it provides less tissue architecture. Biopsy planning seeks to avoid traversing an uninvolved pleural space because of the risk of tumor-cell seeding. (gethi.org)\n\nEvaluation also addresses immune-associated illness that can alter procedural risk. History and physical examination assess neurological weakness and evidence of infection or anemia. Acetylcholine-receptor antibody testing contributes to evaluation for myasthenia gravis, particularly before surgery and anesthesia. A complete blood count with reticulocytes assesses cytopenias and impaired red-cell production; serum protein electrophoresis and quantitative immunoglobulin measurements investigate hypogammaglobulinemia associated with Good syndrome. These investigations characterize accompanying disorders rather than diagnose thymoma: the American Cancer Society explicitly distinguishes their supportive role from the tissue examination needed to establish the tumor diagnosis. (thymicuk.org)"
    },
    {
      "heading": "Anatomical Spread and Staging Systems",
      "text": "Thymoma can extend directly from the thymus into mediastinal fat and pleura, then invade adjacent structures such as the pericardium, lung, phrenic nerve, or major vessels. Contiguous invasion is distinguished from separate tumor deposits: extension into the immediately adjacent lung contributes to the primary-tumor category, whereas a separate intrapulmonary metastasis contributes to the metastasis category. Likewise, direct pericardial invasion differs from discontinuous nodules on the pericardial surface. Pleural or pericardial dissemination, spread to regional lymph nodes, and distant metastasis are therefore recorded separately rather than treated as equivalent forms of local extension. (itmig.org)\n\nThe Masaoka–Koga system, originating with Akira Masaoka and colleagues in 1981 and modified by Kenji Koga and colleagues in 1994, combines operative observations with microscopic assessment. Stage I denotes an encapsulated tumor without extension through its capsule; invasion into, but not through, the capsule does not itself establish stage II. Stage IIA denotes microscopic transcapsular invasion, while IIB denotes gross extension into surrounding thymic or mediastinal fat, including gross adherence to the pleura or pericardium without penetration. Stage III denotes invasion of neighboring organs, including the pericardium, lung, or great vessels. Stage IVA denotes separate pleural or pericardial dissemination; IVB denotes lymphogenous or hematogenous metastases. Its longstanding use in surgical series makes it essential when interpreting historical outcome studies, but its categories are not interchangeable with TNM stages. (cancer.gov)\n\nThe ninth-edition TNM classification, used for thymic epithelial tumors from January 2025, separates primary-tumor extent (T), regional nodal involvement (N), and metastases (M). In the IASLC framework, T1 includes tumors confined to the thymus or extending into mediastinal fat or mediastinal pleura; T1a measures \\(\\leq 5\\) cm and T1b measures \\(>5\\) cm in greatest dimension. T2 denotes direct invasion of the pericardium, lung, or phrenic nerve. T3 denotes invasion of the brachiocephalic vein, superior vena cava, chest wall, or extrapericardial pulmonary arteries or veins. T4 denotes invasion of the aorta or arch vessels, intrapericardial pulmonary arteries or veins, myocardium, trachea, or esophagus. (itmig.org)\n\nN0 indicates no regional nodal metastasis, N1 involvement of anterior perithymic or prevascular nodes, and N2 involvement of deep intrathoracic or cervical nodes. M0 indicates no pleural, pericardial, or distant metastasis; M1a denotes separate pleural or pericardial nodules; M1b denotes distant metastasis, including separate pulmonary intraparenchymal nodules. With N0M0 disease, T1, T2, T3, and T4 correspond respectively to stages I, II, IIIA, and IIIB. IVA comprises any T with N1M0, or M1a disease with N0 or N1. IVB comprises N2 disease with M0 or M1a, or any M1b disease regardless of T or N. Thus, anterior nodal metastasis is TNM IVA, although nodal spread belongs to IVB in Masaoka–Koga. (iaslc.org)\n\nClinical staging—prefixed c—uses pretreatment examination, imaging, and available tissue findings; pathological staging—prefixed p—incorporates surgical and microscopic findings, with histological confirmation required for invasion. These assessments can differ when microscopic extension is not visible on imaging. The system and edition must accompany a reported stage: a tumor invading mediastinal fat can be Masaoka–Koga II but ninth-edition TNM I if N0M0. Edition changes also matter: lung and phrenic-nerve invasion moved from T3 in the eighth edition to T2 in the ninth, and T1 subdivision changed from mediastinal-pleural involvement to the 5-cm size threshold. (cancer.org)"
    },
    {
      "heading": "Surgery and Radiotherapy for Localized or Locally Advanced Disease",
      "text": "Complete surgical removal is the principal local treatment when thymoma can be fully resected. Thymectomy generally removes the tumor, the remaining thymus, and surrounding thymic fat, rather than simply shelling out the mass. For invasive tumors, en bloc resection removes the tumor together with involved adjacent structures, which may include portions of pericardium, lung, or major veins. The objective is an R0 resection: no residual tumor, with microscopically negative surgical margins. R1 denotes microscopic residual disease, whereas R2 denotes visible residual tumor. These distinctions influence subsequent radiotherapy. Median sternotomy provides access for extensive operations; minimally invasive surgery, including thoracoscopic or robotic approaches, is used for selected apparently early-stage tumors when complete removal can be maintained. (pmc.ncbi.nlm.nih.gov)\n\nSurgery alone is established treatment for completely resected, encapsulated, noninvasive thymoma. In the Masaoka–Koga terminology used by much of the treatment literature, this corresponds to stage I; postoperative radiotherapy has not demonstrated benefit in this setting. Management after R0 resection of stage II disease is less uniform. Retrospective studies give conflicting results, and prospective randomized evidence is lacking. Consequently, postoperative radiotherapy is used selectively according to the extent of invasion, histological subtype, and proximity of tumor to the resection margin. The 2021 GOECP/SEOR guidelines, for example, distinguish completely resected stage IIA types A–B2, for which no adjuvant treatment is specified, from type B3, for which radiotherapy may be considered. These historical stage labels are not interchangeable with TNM stage groups. (cancer.gov)\n\nPostoperative radiotherapy is more consistently incorporated after resection of locally invasive stage III thymoma and after microscopically incomplete resection. Its purpose is to control disease remaining, or potentially remaining, in the operative bed. The 2021 GOECP/SEOR guidance describes approximately 45–50 Gy after R0 resection when irradiation is indicated, 50–54 Gy for microscopic residual disease, and 60–70 Gy for gross residual disease, generally using conventional fractionation. Treatment planning uses the preoperative tumor extent, operative findings, and margin assessment; surgical clips can identify uncertain margins. Conformal techniques, particularly intensity-modulated radiotherapy, shape the dose around the target while limiting exposure of nearby organs. The SEOM-GECP-GETTHI guidelines specifically emphasize preservation of normal lung and heart. (pmc.ncbi.nlm.nih.gov)\n\nLocally advanced disease is managed according to whether complete resection appears achievable, not anatomical stage alone. A resectable invasive tumor may undergo surgery followed by radiotherapy. When initial complete removal is unlikely, tissue confirmation precedes induction chemotherapy, sometimes combined with radiotherapy, intended to reduce tumor extent before another assessment of operability. Imaging reassessment then determines whether surgery can proceed; a radiological response does not itself establish that an R0 resection is possible. Published induction series summarized by the National Cancer Institute reported response rates of 79–100%, but subsequent resectability rates of only 36–69%, illustrating the difference between tumor shrinkage and surgical clearance. (cancer.gov)\n\nIf disease remains unresectable, or an operation is not feasible, definitive radiotherapy—with or without chemotherapy—provides a nonsurgical local-treatment pathway. The SEOM-GECP-GETTHI guidelines describe definitive doses of 60–66 Gy and concurrent platinum–etoposide chemotherapy in selected circumstances. This differs from lower-dose postoperative irradiation directed at possible microscopic disease. Debulking that deliberately leaves substantial visible tumor is not equivalent to complete resection: its contribution remains uncertain, and combined chemotherapy and radiotherapy can be used without an intervening operation. (pmc.ncbi.nlm.nih.gov)"
    },
    {
      "heading": "Systemic Treatment and Recurrent Disease",
      "text": "Platinum-based combination chemotherapy is used both to reduce initially unresectable thymoma before local treatment and to control disseminated disease. A commonly used regimen is cisplatin, doxorubicin, and cyclophosphamide, abbreviated CAP or PAC. In the induction setting, chemotherapy is followed by reassessment for complete resection; in disseminated disease not amenable to definitive local treatment, its purpose is disease control rather than preparation for an operation. These treatment intentions are distinct even when the drugs are identical. (cancer.gov) In the intergroup trial reported by Patrick J. Loehrer and colleagues in 1994, 30 assessable patients—29 with thymoma and one with thymic carcinoma—received PAC for metastatic or locally progressive recurrent disease after radiotherapy. The objective response rate was 50%, providing an early prospective demonstration of activity, although this small, predominantly thymoma cohort was not a randomized comparison. (scholars.mssm.edu)\n\nRecurrence does not automatically imply a switch to systemic treatment. Its anatomical distribution, potential for complete removal, and previous treatment determine the documented use of repeat surgery, radiotherapy, or drug therapy. A limited recurrence in or near the original site may be treated locally, whereas widespread disease generally requires a systemic approach. Previous irradiation affects the feasibility of further radiotherapy. (cancer.org) Previous drug response and the treatment-free interval also matter: combination chemotherapy has been reused in selected patients with a durable earlier response and adequate functional status. Prior cumulative anthracycline exposure constrains further doxorubicin treatment because of cardiac toxicity. (cancer.gov)\n\nSubsequent-line cytotoxic evidence comes largely from small phase II studies rather than head-to-head trials. In a 2018 pemetrexed study enrolling 16 patients with thymoma and 11 with thymic carcinoma, four evaluable thymoma patients responded, including two complete responses; median progression-free survival in the thymoma subgroup was 12.1 months. (pubmed.ncbi.nlm.nih.gov) A separate capecitabine–gemcitabine trial documented objective responses in 9 of 22 patients with recurrent thymoma, or 41%, with median progression-free survival of 11 months. These results establish activity but do not establish superiority over other subsequent-line regimens. Octreotide, with or without the corticosteroid prednisone, has also produced responses in thymomas showing uptake on octreotide imaging, an example of treatment selection based on demonstrable somatostatin-receptor targeting. (cancer.gov)\n\nTargeted-treatment results must be separated by histological diagnosis. In Paolo Andrea Zucali and colleagues’ 2018 phase II study, the mTOR inhibitor everolimus produced partial responses in 3 of 32 patients with thymoma and stable disease in another 27: the 93.8% disease-control rate therefore predominantly represented stabilization, not tumor shrinkage. Three patients in the combined 50-patient thymoma–carcinoma population died of pneumonitis, an important toxicity alongside the activity signal. (pubmed.ncbi.nlm.nih.gov) Likewise, a 2015 sunitinib trial found a partial response in only 1 of 16 thymoma patients, compared with 6 of 23 assessable thymic carcinoma patients. The carcinoma response rate cannot be transferred to thymoma. (pubmed.ncbi.nlm.nih.gov)\n\nImmune-checkpoint inhibitors present a particular safety problem in thymoma. Jinhyun Cho and colleagues’ phase II pembrolizumab trial, published in its final journal issue in 2019, recorded partial responses in 2 of 7 thymoma patients, but grade 3 or higher immune-related adverse events in 5 of 7, or 71.4%. Across the study, serious immune toxicities included myocarditis, hepatitis, and myasthenia gravis. These events occurred despite exclusion of patients with specified active or clinically severe autoimmune disease. The thymoma subgroup’s toxicity rate was substantially higher than the 15.4% observed among the 26 thymic carcinoma patients, illustrating why evidence for checkpoint blockade in these two diagnoses must remain separate. (pubmed.ncbi.nlm.nih.gov)"
    },
    {
      "heading": "Prognosis and Long-Term Clinical Course",
      "text": "Anatomical stage and completeness of resection are major determinants of thymoma prognosis. Tumors confined to the thymus generally have more favorable outcomes than those invading neighboring organs or producing separate pleural or distant deposits. Complete resection with microscopically negative margins—an R0 resection—is associated with better disease control than resection leaving microscopic or visible tumor. Histological subtype adds prognostic information: types B2 and B3 generally recur more often than types A, AB, and B1, although histology and stage are correlated, and subtype does not replace anatomical assessment. In a 2013 retrospective study by Mi Kyung Bae and colleagues, involving 305 patients operated on between 1986 and 2009, observed recurrence proportions were 6.1%, 11.4%, 26.8%, and 50.0% for Masaoka stages I–IV, respectively. These were cohort-specific proportions over follow-up, not fixed-time recurrence probabilities; stage remained independently associated with recurrence in the study’s adjusted analysis. (cancer.gov)\n\nOutcome measures describe different aspects of this often prolonged course. Overall survival counts death from any cause, including unrelated illness; disease-specific survival focuses on deaths attributed to thymoma, with attribution rules requiring particular care when treatment complications or associated immune disorders are involved. Recurrence-free survival generally measures time without recurrence or death after disease-eradicating treatment, whereas freedom from recurrence isolates tumor relapse and handles deaths without relapse separately. Consequently, these measures cannot be interchanged. Standardized reporting developed by James Huang, Frank Detterbeck, and colleagues emphasizes this distinction because patients may survive for years after recurrence, while others die without recurrent tumor. (pmc.ncbi.nlm.nih.gov)\n\nLate recurrence makes a five-year disease-free interval an incomplete description of long-term risk. In Bae and colleagues’ series, the median time to recurrence was 52 months, but the range extended from 6 to 234 months—nearly 20 years. Regional recurrence was more frequent than isolated local recurrence or distant metastasis. Prolonged clinical review and thoracic imaging, commonly computed tomography, therefore serve to detect recurrent disease, assess new symptoms, and identify delayed treatment effects. The National Cancer Institute notes that very late relapse supports consideration of lifelong surveillance; the frequency and duration of imaging depend on the original disease and treatment rather than a single universal schedule. (pmc.ncbi.nlm.nih.gov)\n\nTumor control does not necessarily resolve immune-associated illness. Myasthenia gravis and other paraneoplastic disorders may persist after resection and follow a course partly independent of measurable tumor burden. Good syndrome provides a particularly clear example: in a 2018 UK series of 78 patients, thymectomy did not improve hypogammaglobulinemia or B-cell deficiency. Persistent immunodeficiency leaves infections clinically relevant even when the tumor has been removed. Long-term morbidity also depends on treatment exposure: chest radiotherapy and certain chemotherapy drugs can produce cardiac injury that becomes apparent years later, while irradiation involving lung tissue can cause lasting pulmonary damage. These late effects are distinct from recurrent thymoma, although their symptoms may overlap. (cancer.gov)\n\nAdditional primary malignancies are another documented feature of survivorship and must be distinguished from thymoma metastases. A population-based study of 849 thymoma cases diagnosed between 1973 and 1998 found excess subsequent non-Hodgkin lymphoma and soft-tissue sarcoma. This association does not establish that thymoma itself causes the later cancers. The studies summarized by the National Cancer Institute did not find the excess clearly related to thymectomy, radiotherapy, or a clinical history of myasthenia gravis; these observations likewise do not establish a single alternative mechanism for the association. (cancer.gov)"
    },
    {
      "heading": "Development of Classification and Clinical Evidence",
      "text": "Older thymoma classifications emphasized either the relative abundance of epithelial cells and lymphocytes—producing labels such as epithelial-predominant, lymphocyte-predominant, and mixed thymoma—or resemblance to normal thymic compartments, expressed as cortical and medullary terminology. These competing approaches complicated comparisons between published series. The 1999 World Health Organization classification, edited by Juan Rosai, introduced the standardized A, AB, and B1–B3 nomenclature, which subsequent editions retained. Historical terminology nevertheless requires careful interpretation: “type C thymoma” referred to thymic carcinoma, classified separately in the 2004 edition, rather than to another subtype within the present thymoma spectrum. Older diagnostic labels therefore cannot always be pooled directly with modern categories. (pmc.ncbi.nlm.nih.gov)\n\nStandardization also required more reproducible diagnostic boundaries. In a consensus study published in 2014, Alexander Marx and colleagues reported an International Thymic Malignancy Interest Group (ITMIG) workshop in which 18 pathologists examined 72 prototypical, borderline, and combined thymic epithelial tumors. The group refined criteria for distinguishing A from AB, separating B1, B2, and B3, and differentiating B3 thymoma from thymic carcinoma. These refinements informed the 2015 WHO classification. The International Collaboration on Cancer Reporting subsequently translated classification into structured reporting: its 2022 thymic dataset follows the 2021 WHO classification and records mixed histological components in 10% increments, alongside anatomical invasion, margins, and nodal findings. Such structured observations make cases more comparable across institutions than a diagnostic name alone. (pubmed.ncbi.nlm.nih.gov)\n\nInternational collaboration similarly transformed anatomical staging from predominantly institutional experience into large-scale pooled analysis. The International Association for the Study of Lung Cancer (IASLC) and ITMIG assembled 10,808 thymic malignancies from 105 sites for development of the eighth-edition TNM framework. Contributions combined ITMIG’s international collection with Japanese and European databases. Shared descriptions of invaded structures allowed investigators to test anatomical groupings against outcomes, rather than relying on inconsistently interpreted terms such as “invasive thymoma.” The database informing ninth-edition proposals, described by Andreas Rimner and colleagues in 2023, received 11,347 cases, of which 9,147 were eligible for analysis. These totals encompass several thymic epithelial tumor categories, not thymoma alone; participating organizations included Japanese, European, Chinese, Korean, international, and French collaborative networks. (doi.org)\n\nClinical evidence has developed through complementary but unequal sources. Population registries supply incidence and long-term outcome information, while institutional and collaborative retrospective series relate stage, histology, resection, and treatment to subsequent outcomes. Prospective clinical trials provide more consistently defined eligibility, treatment, and response assessment, but frequently enroll only a few dozen patients. For example, Patrick J. Loehrer Sr. and colleagues’ 1994 intergroup chemotherapy study included 30 assessable patients—29 with thymoma and one with thymic carcinoma. Its objective response rate was 50%, but the 95% confidence interval extended from 31.3% to 68.7%, illustrating the uncertainty accompanying small samples. Without a randomized comparator, such a study establishes activity rather than comparative superiority. (cancer.gov)\n\nRarity and heterogeneity limit both treatment comparisons and biomarker validation. Retrospective treatment groups differ in resectability, stage, and completeness of resection, factors themselves associated with outcome; an observed survival difference therefore does not necessarily measure treatment effect. Changing diagnostic criteria further complicate historical comparisons. Pooling thymoma with thymic carcinoma increases recruitment but may obscure different responses: an NCI-reviewed sunitinib trial reported objective responses in one of 16 thymoma patients, compared with six of 23 assessable thymic carcinoma patients. Subdivision by histology and candidate molecular marker leaves still smaller groups for predictive analyses, making independent validation difficult and preventing a molecular association alone from establishing a treatment-selection test. (cancer.gov)"
    }
  ],
  "links": [
    "thymus",
    "t-cell",
    "immune-system",
    "radiation-therapy",
    "lymphocyte",
    "lymphoma",
    "world-health-organization",
    "incidence",
    "autoimmune-disease",
    "dna-sequencing",
    "biomarker",
    "central-immune-tolerance",
    "autoimmune-regulator",
    "autoimmunity",
    "gene-expression",
    "x-ray-computed-tomography",
    "cough",
    "shortness-of-breath",
    "autoantibody",
    "erythrocyte",
    "anemia",
    "bone-marrow",
    "immunodeficiency",
    "magnetic-resonance-imaging",
    "contrast-agent",
    "biopsy",
    "pathology",
    "physical-examination",
    "complete-blood-count",
    "lymph-node",
    "surgery",
    "minimally-invasive-surgery",
    "chemotherapy",
    "corticosteroid",
    "immune-checkpoint-inhibitor",
    "clinical-trial"
  ],
  "sources": [
    {
      "title": "Thymoma and Thymic Carcinoma",
      "url": "https://www.cancer.gov/types/thymus-cancer/thymoma-thymic-carcinoma?cid=ehr_medlineplus_en_thymoma"
    },
    {
      "title": "Thymus | SEER Training",
      "url": "https://training.seer.cancer.gov/anatomy/lymphatic/components/thymus.html"
    },
    {
      "title": "Thymic Epithelial Tumours Histopathology Reporting Guide, 3rd edition",
      "url": "https://www.iccr-cancer.org/wp-content/uploads/2022/08/ICCR-Thymus-3rd-ed-v1.0-bookmark.pdf"
    },
    {
      "title": "Thymic Epithelial Tumours",
      "url": "https://www.iccr-cancer.org/datasets/published-datasets/thorax/thymic-epithelial/"
    },
    {
      "title": "Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version",
      "url": "https://www.cancer.gov/types/thymus-cancer/hp/thymoma-treatment-pdq"
    },
    {
      "title": "Epidemiology of thymoma and associated malignancies",
      "url": "https://pubmed.ncbi.nlm.nih.gov/20859116/"
    },
    {
      "title": "Thymus Cancer Causes, Risk Factors, and Prevention",
      "url": "https://www.cancer.org/cancer/types/thymus-cancer/causes-risks-prevention.html"
    },
    {
      "title": "ITMIG Consensus Statement on the Use of the WHO Histological Classification of Thymoma and Thymic Carcinoma: Refined Definitions, Histological Criteria, and Reporting",
      "url": "https://thymic.org/wp-content/uploads/2021/05/ITMIG_Consensus_Statement_on-classification.pdf"
    },
    {
      "title": "The 2015 WHO Classification of Tumors of the Thymus: Continuity and Changes",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4581965/"
    },
    {
      "title": "The integrated genomic landscape of thymic epithelial tumors",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5994906/"
    },
    {
      "title": "Thymoma Study",
      "url": "https://www.cancer.gov/ccg/research/genome-sequencing/tcga/studied-cancers/thymoma-study"
    },
    {
      "title": "A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5705185/"
    },
    {
      "title": "Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2219324/"
    },
    {
      "title": "The Integrated Genomic Landscape of Thymic Epithelial Tumors",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29438696/"
    },
    {
      "title": "Altered Thymopoiesis in Thymoma Is Associated with Defects in Negative Selection Machinery and Decreased Treg Abundance",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41143696/"
    },
    {
      "title": "Signs and Symptoms of Thymus Cancers",
      "url": "https://www.cancer.org/cancer/types/thymus-cancer/detection-diagnosis-staging/signs-symptoms.html"
    },
    {
      "title": "Myasthenia Gravis",
      "url": "https://www.ninds.nih.gov/sites/default/files/2025-05/myasthenia-gravis.pdf"
    },
    {
      "title": "Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group",
      "url": "https://haematologica.org/article/view/4712"
    },
    {
      "title": "Clinical manifestations and long-term prognosis of Good syndrome: Results from a single-center cohort study from China",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33428506/"
    },
    {
      "title": "Tests for Thymus Cancer | American Cancer Society",
      "url": "https://www.cancer.org/cancer/types/thymus-cancer/detection-diagnosis-staging/how-diagnosed.html"
    },
    {
      "title": "SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021)",
      "url": "https://www.gethi.org/modulgex/workspace/publico/modulos/web/docs/apartados/157/280622_102621_5476150113.pdf"
    },
    {
      "title": "Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up",
      "url": "https://thymicuk.org/wp-content/uploads/2019/10/ESMO-Guidelines-Thymic-Epithelial-Tumours.pdf"
    },
    {
      "title": "Imaging of thymic epithelial tumors—a clinical practice review",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11330907/"
    },
    {
      "title": "ITMIG – Staging",
      "url": "https://itmig.org/about-thymic-tumors/staging/"
    },
    {
      "title": "The Masaoka-Koga Stage Classification for Thymic Malignancies: Clarification and Definition of Terms",
      "url": "https://scispace.com/pdf/the-masaoka-koga-stage-classification-for-thymic-9ji0l9e1m1.pdf"
    },
    {
      "title": "Thymic Epithelial Tumours: Histopathology Reporting Guide",
      "url": "https://itmig.org/wp-content/uploads/2022/06/ICCR-Thymic-Epithelial-Tumours-Histopathology-Reporting-Guide.pdf"
    },
    {
      "title": "IASLC Thymic Epithelial Tumors TNM Stages–9th Edition",
      "url": "https://www.iaslc.org/file/10871/download?token=DmNIDkWP"
    },
    {
      "title": "IASLC Staging Manual in Thoracic Oncology",
      "url": "https://www.iaslc.org/file/10870/download?token=ZdsZFnAS"
    },
    {
      "title": "Thymus Cancer Stages",
      "url": "https://www.cancer.org/cancer/types/thymus-cancer/detection-diagnosis-staging/staging.html"
    },
    {
      "title": "GOECP/SEOR radiotherapy guidelines for thymic epithelial tumours",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085511/"
    },
    {
      "title": "SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021)",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8817662/"
    },
    {
      "title": "Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: Final results of an intergroup trial",
      "url": "https://scholars.mssm.edu/en/publications/cisplatin-plus-doxorubicin-plus-cyclophosphamide-in-metastatic-or-2/"
    },
    {
      "title": "Treating Thymus Cancers by Extent and Type of Tumor",
      "url": "https://www.cancer.org/cancer/types/thymus-cancer/treating/by-extent.html"
    },
    {
      "title": "A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma",
      "url": "https://pubmed.ncbi.nlm.nih.gov/30121390/"
    },
    {
      "title": "Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29240542/"
    },
    {
      "title": "Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial",
      "url": "https://pubmed.ncbi.nlm.nih.gov/25592632/"
    },
    {
      "title": "Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29906252/"
    },
    {
      "title": "Predictors of recurrence after thymoma resection",
      "url": "https://pubmed.ncbi.nlm.nih.gov/23709420/"
    },
    {
      "title": "Predictors of Recurrence after Thymoma Resection",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3663243/"
    },
    {
      "title": "Standard Outcome Measures for Thymic Malignancies",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6131238/"
    },
    {
      "title": "After Thymus Cancer Treatment",
      "url": "https://www.cancer.org/cancer/types/thymus-cancer/after-treatment.html"
    },
    {
      "title": "Clinical and laboratory features of seventy-eight UK patients with Good’s syndrome (thymoma and hypogammaglobulinaemia)",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6300645/"
    },
    {
      "title": "Coping – Late Effects",
      "url": "https://www.cancer.gov/about-cancer/coping/survivorship/late-effects"
    },
    {
      "title": "Diagnosis of thymoma",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC1860528/"
    },
    {
      "title": "Pathological aspects of malignant and benign thymic disorders",
      "url": "https://pubmed.ncbi.nlm.nih.gov/10574149/"
    },
    {
      "title": "ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting",
      "url": "https://pubmed.ncbi.nlm.nih.gov/24722150/"
    },
    {
      "title": "The IASLC/ITMIG Thymic Malignancies Staging Project: Development of a Stage Classification for Thymic Malignancies",
      "url": "https://doi.org/10.1097/JTO.0000000000000017"
    },
    {
      "title": "The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposals for the T Component for the forthcoming (8th) edition of the TNM classification of malignant tumors",
      "url": "https://iris.uniroma1.it/handle/11573/829528"
    },
    {
      "title": "The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: An Overview of the Central Database Informing Revision of the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37702630/"
    },
    {
      "title": "Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial",
      "url": "https://pubmed.ncbi.nlm.nih.gov/8201378/"
    }
  ],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}